Description Module
The Description Module contains narrative descriptions of the clinical trial, including a brief summary and detailed description. These descriptions provide important information about the study's purpose, methodology, and key details in language accessible to both researchers and the general public.
Description Module path is as follows:
Study -> Protocol Section -> Description Module
Description Module
Ignite Creation Date:
2025-12-24 @ 10:56 PM
Ignite Modification Date:
2025-12-24 @ 10:56 PM
NCT ID:
NCT06241469
Brief Summary:
The goal of this clinical trial is to find better protocal for adenocarcinoma of the gastric and gastroesophageal juncion.
The main question is aim to answer is:
1\. The efficacy and safety of PD-1 monoclonal antibody (Sintilimab) combined with nab-paclitaxel and S-1 in the first-line treatment of advanced gastric and gastroesophageal junction adenocarcinoma.
Participants will be given PD-1 monoclonal antibody, nab-paclitaxel and tegio.
Study:
NCT06241469
Study Brief:
Protocol Section:
NCT06241469